Congress Materials – World Congress of Pediatric Dermatology (WCPD 2025)

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Results of Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)

Lawrence Eichenfield, Ricardo Galimberti, Adelaide Hebert, Wenhui Wang, Jennifer Soung, Nina Magnolo, John C. Browning, Angela Moore, Mark Lebwohl, Dagmar Wilsmann-Theis, Georgios Kokolakis, Dariusch Mortazawi, Parbeer Grewal, Megan Miller, Joseph Cafone*, Shu Li, Gigi Jiang, Fabio Nunes, Cynthia DeKlotz, Amy Paller

 

View poster